The efficacy and tolerability of intermediate high dose interferon alpha 2B treatment as an adjuvant therapy of high risk malignant melanoma Yüksek riskli malign melanomun adjuvan tedavisinde orta yüksek doz i̇nterferon alfa-2B tedavisinin etkinliǧi ve tolerabilitesi

Karabulut B., Sezgin V. C., Göksel G., Şanli U. A., Uslu R., Göker E.

THOD - Turk Hematoloji-Onkoloji Dergisi, cilt.15, sa.1, ss.6-14, 2005 (Scopus, TRDizin) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 1
  • Basım Tarihi: 2005
  • Dergi Adı: THOD - Turk Hematoloji-Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.6-14
  • Anahtar Kelimeler: Adjuvant therapy, Interferon alpha 2B, Malignant melanoma
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

There are still ongoing clinical trials and debates about adjuvant treatment of malignant melanoma. Between 1995 and 2004, fourty-nine patients with high risk operated non-metastatic malignant melanoma who had been treated with intermediate dose of interferon alpha were enrolled to the study. Twenty-three patients had regional lymph node metastasis at the time of diagnosis. Patients were treated with interferon alpha 2b (10 million units/day, five times a week for four weeks) as an induction therapy, followed by interferon alpha 2b (10 million units/day interferon three times a week for eleven months) as a maintanence therapy. The median follow-up time was 35 months (range 2-101 months). In this period, 7(14%) of patients had local recurrence, 12 (24%) of patients had regional lymph node metastasis and 20 (41%) of patients had distant metastasis. The 5-years overall survival, disease free survival and distant metastasis free survival rate of patients were 68%, 32% and 54% respectively. Therapy was well tolerated, no grade 4 toxicity related to therapy was observed. Comparing to natural history of malignant melanoma, these results are found to be encouraged.